Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Adv Gerontol ; 33(6): 1150-1157, 2020.
Artigo em Russo | MEDLINE | ID: mdl-33774999

RESUMO

Anemic syndrome is common in 1/3 of the population, including iron deficiency anemia - in 1,5 billion people. Geriatric patients are one of the main risk group for anemia. Iron deficiency and iron deficiency anemia lead to a decrease in quality of life, an increase in morbidity and mortality, what requires timely diagnosis and treatment. The diagnostic algorithm includes the analysis of iron metabolism, inflammation markers and instrumental tests to verify the cause of anemia. Modern oral and parenteral iron preparations are used for treatment under control of blood indexes and iron metabolism parameters.


Assuntos
Anemia Ferropriva , Anemia , Idoso , Anemia Ferropriva/diagnóstico , Anemia Ferropriva/epidemiologia , Anemia Ferropriva/etiologia , Humanos , Ferro , Qualidade de Vida , Fatores de Risco
2.
Vopr Onkol ; 62(4): 429-38, 2016.
Artigo em Russo | MEDLINE | ID: mdl-30475526

RESUMO

Over the past decades the studies have greatly improved our understanding of the molecular basis of multiple myeloma (MM) and mechanisms of disease progression. The majority of the most widespread chromosomal aberrations, revealing in MM, has independent predictive value and influence on a choice of optimal treatment. There were observed 190 MM patients in hematologic hospitals of St. Petersburg. Genetic anomalies (GA) were detected at 3l,3% of patients and did not depend on their age. Patients with ISS III had a detectability of GA higher than with ISS II and ISS I (48,°% (24/5°), 2l,2% (7/33) and 27,6% (8/29)). Translocation t(ll;l4) was found in 23,3% (3O/129) patients; dell3q - 20,8% (27/13°); dell7p - at 8,4% (7/83); t(4;l4) - at 6,9% (9/13O), that allowed to stratify patients in groups of risk according to mSMART version l. O and 2. O. Median overall survival (OS) modified mSMART l. O in group of standard risk was 7° months, high risk - 47,l months. Median OS mSMART 2. O in group of standard risk was 7° months, intermediate risk - 47 months, high risk - 45 months. OS did not depend on age, clinical manifestations, treatment and other factors.


Assuntos
Aberrações Cromossômicas/classificação , Mieloma Múltiplo/diagnóstico , Mieloma Múltiplo/genética , Translocação Genética/genética , Adulto , Idoso , Idoso de 80 Anos ou mais , Cromossomos/genética , Feminino , Humanos , Cariótipo , Masculino , Pessoa de Meia-Idade , Mieloma Múltiplo/classificação , Mieloma Múltiplo/patologia
3.
Vestn Ross Akad Med Nauk ; (10): 32-6, 1998.
Artigo em Russo | MEDLINE | ID: mdl-9846110

RESUMO

Sixty six patients with non-Hodgkin's lymphomas (NHL) were studied, interleukin-6 (IL-6) was revealed in the blood sera of 33 patients. IL-6 was revealed more frequently in patients with high-grade malignant (p < 0.05) than in those with low-grade malignancy. The largest group of IL-6 positive patients included NHL patients with diffuse large B-cell lymphoma and angioimmunoblastic lymphoma. The marked relationship was found between the serum IL-6 levels and the stage of disease: the serum IL-6 level was significantly lower in untreated patients with Stages II and III disease than in those with end-stage (IV) NHL. IL-6 significantly decreased upon remission, comparable with its level before the initiation of treatment. Analysing the association of prognosis of disease with the serum IL-6 showed that in the group of patients with good (The SNLG index < 2) and intermediate (2 < SNLG index < by 2.6) prognosis, the concentration of this cytokine was significantly lower than in those with poor prognosis (SNLG index > 2.6). There was a significant decrease of the total survival rates of NHL with serum IL-6 found. Therefore, IL-6 is a good prognostic marker in NHL and associated with the activity of a malignant process. Additionally, the increased serum IL-6 levels correlated with NK activities positively and with serum IL-4 levels negatively.


Assuntos
Interleucina-6/sangue , Linfoma de Células B/diagnóstico , Adolescente , Adulto , Idoso , Biomarcadores Tumorais/sangue , Diagnóstico Diferencial , Feminino , Seguimentos , Humanos , Linfadenopatia Imunoblástica/sangue , Linfadenopatia Imunoblástica/diagnóstico , Linfadenopatia Imunoblástica/mortalidade , Linfoma de Células B/sangue , Linfoma de Células B/mortalidade , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Prognóstico , Estudos Retrospectivos , Taxa de Sobrevida
5.
Vopr Virusol ; 43(2): 79-82, 1998.
Artigo em Russo | MEDLINE | ID: mdl-9606876

RESUMO

Thirty-four primary (untreated) patients with non-Hodgkin's lymphomas (NHL) infected with Epstein-Barr virus (EBV) were examined. Their HLA phenotype and the production of interleukin-1 beta and tumor necrosis factor alpha were assessed. Serological profiles characteristic of the late stages and reactivation of EBV infection were detected in 16 (47.1%) patients. NHL of low malignancy predominated in EBV-infected patients. A greater number of blank HLA-A antigens and a higher incidence of HLA-DR7 antigen was observed in infected patients. Serum concentration of tumor necrosis factor alpha was reliably higher in them, whereas the production of this cytokine by the peripheral blood mononuclears decreased. Hence, serum tumor necrosis factor is a product of transformed B lymphocytes. Spontaneous and stimulated production of interleukin-1 beta by peripheral blood mononuclears was significantly decreased in EBV-infected patients, and the serum concentration of this cytokine similarly had a trend to decrease, which indicates an inhibition of interleukin-1 beta production in EBV-infected patients with NHL.


Assuntos
Antígenos HLA/imunologia , Antígeno HLA-DR7/imunologia , Herpesvirus Humano 4/isolamento & purificação , Interleucina-1/biossíntese , Linfoma não Hodgkin/imunologia , Fator de Necrose Tumoral alfa/biossíntese , Infecções Tumorais por Vírus/imunologia , Feminino , Humanos , Imunofenotipagem , Linfoma não Hodgkin/complicações , Linfoma não Hodgkin/metabolismo , Masculino , Pessoa de Meia-Idade , Infecções Tumorais por Vírus/complicações , Infecções Tumorais por Vírus/metabolismo
6.
Radiats Biol Radioecol ; 34(1): 138-42, 1994.
Artigo em Russo | MEDLINE | ID: mdl-8148969

RESUMO

CM-5 fraction of tortoise spleen extract injected after irradiation in dose CD50/30 (540 R) raises a survival of mice to 73.4%. The number of endocolonies of spleen increases to 4.0 in experiment against 0.3 in control and the average life of experimental animals increases to 12.7 days against 8.8 in control. In vitro it has been found a considerable increase of RNA-synthetic activity of bone marrow cells stimulated by CM-5 fraction in post-irradiation period. The dose alteration factor for CM-5 fraction is 1.46 according to CD50/30 standard at survival test.


Assuntos
Lesões Experimentais por Radiação/tratamento farmacológico , Protetores contra Radiação/uso terapêutico , Baço , Extratos de Tecidos/uso terapêutico , Tartarugas , Animais , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos , Feminino , Masculino , Camundongos , Lesões Experimentais por Radiação/mortalidade , Fatores de Tempo , Irradiação Corporal Total
8.
Gig Sanit ; (6): 15-7, 1991 Jun.
Artigo em Russo | MEDLINE | ID: mdl-1769568

RESUMO

In the experiments with white rats it was found, that the inhalation of freon 114B2 at CL16, CL50, CL84 levels caused the changes in seasonal values of the energy activity in mitochondria. The action of the freon 114B2 caused disturbances in regulation of the mitochondria activity and desynchronization of seasonal rhythms of their energy activity.


Assuntos
Clorofluorcarbonetos de Metano/toxicidade , Metabolismo Energético/efeitos dos fármacos , Mitocôndrias Hepáticas/efeitos dos fármacos , Estações do Ano , Animais , Bromoclorofluorcarbonos , Humanos , Masculino , Mitocôndrias Hepáticas/enzimologia , Ratos
10.
Gig Sanit ; (3): 32-4, 1989 Mar.
Artigo em Russo | MEDLINE | ID: mdl-2744501

RESUMO

The study revealed that after benzene-induced intoxication (CI50) there occurred low-energetic and energetic phase shifts in rats' liver mitochondria. The content of lipid peroxidation products of the above organellas varied analogously. The time following intoxication being longer, higher were the general level of liver mitochondria energetic activity and the content of lipid peroxidation products. The highest level was recorded on the 3d day after benzen-induced intoxication. On the 16th day complete recovery of liver mitochondria was not recorded.


Assuntos
Benzeno/intoxicação , Peroxidação de Lipídeos , Mitocôndrias Hepáticas/metabolismo , Fosforilação Oxidativa , Doença Aguda , Animais , Masculino , Ratos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...